Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
NeuBase Therapeutics, Inc. | Director | Stock option (right to buy) | 37.6K | Sep 9, 2022 | Direct | ||
BioAge Labs, Inc. | Chief Financial Officer | Common Stock | 22.4K | Sep 25, 2024 | Direct | ||
Gain Therapeutics, Inc. | Director | Stock Option (right to buy) | 15K | Jun 24, 2024 | Direct | ||
Coya Therapeutics, Inc. | Director | Stock Option (right to buy) | 5K | Jan 1, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
BIOA | BioAge Labs, Inc. | Sep 25, 2024 | 0 | $0 | 3 | Sep 25, 2024 | Chief Financial Officer |
GANX | Gain Therapeutics, Inc. | Jun 24, 2024 | 1 | $0 | 4 | Jun 26, 2024 | Director |
COYA | Coya Therapeutics, Inc. | Jan 1, 2024 | 1 | $0 | 4 | Jan 19, 2024 | Director |
GANX | Gain Therapeutics, Inc. | Jun 23, 2023 | 1 | $0 | 4 | Jun 26, 2023 | Director |
COYA | Coya Therapeutics, Inc. | Jan 3, 2023 | 2 | $0 | 4 | Jan 4, 2023 | Director |
COYA | Coya Therapeutics, Inc. | Dec 28, 2022 | 0 | $0 | 3 | Dec 28, 2022 | Director |
GANX | Gain Therapeutics, Inc. | Sep 20, 2022 | 1 | $0 | 4 | Sep 22, 2022 | Director |
NBSE | NeuBase Therapeutics, Inc. | Sep 9, 2022 | 1 | $0 | 4 | Sep 12, 2022 | Director |
NBSE | NeuBase Therapeutics, Inc. | Aug 19, 2021 | 1 | $0 | 4 | Sep 17, 2021 | Director |
NBSE | NeuBase Therapeutics, Inc. | Jun 18, 2021 | 1 | $38K | 4 | Jun 21, 2021 | Director |